• 1
    Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999; 341: 10511062.
  • 2
    National Cancer Institute. SEER cancer statistics review, 1973-1996. NIH Pub. No. 99-2789. Bethesda: National Cancer Institute; 1999.
  • 3
    Rowley JD. Molecular genetics in acute leukemia. Leukemia. 2000; 14: 513517.
  • 4
    Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998; 92: 23222333.
  • 5
    Schoch C, Haferlach T, Haase D, et al. Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients. Br J Haematol. 2001; 112: 118126.
  • 6
    Burnett AK. Tailoring the treatment of acute myeloid leukemia. Curr Opin Hematol. 1999; 6: 247252.
  • 7
    Robinson KA, Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. Int J Epidemiol. 2002; 37: 150153.
  • 8
    Der Simonian R. Maximum likelihood estimation of a mixing distribution. Appl Stat. 1986; 35: 302309.
  • 9
    L'Abbe KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Ann Intern Med. 1987; 107: 224233.
  • 10
    Bishop JF, Matthews JP, Young GA, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood. 1996; 87: 17101717.
  • 11
    Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood. 1996; 88: 28412851.
  • 12
    Buchner T, Hiddemann W, Wormann B, et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood. 1999; 93: 41164124.